GSK2816126 was highly active in inhibiting EZH2 mutated tumor growth with a maximum tolerated dose of 2400 mg by intravenous infusion and a dose-limiting toxicity of hepatic transaminitis (NCT02082977) (Table 1) [44]. Here, EZH2 is linked to neoplasm.